Form 4: Allurion Technologies Chief Medical Officer Granted Stock Options

Ram Chuttani, Chief Medical Officer of Allurion Technologies, was granted stock options for 204,082 shares on May 2, 2024.

Summary

• On May 2, 2024, Ram Chuttani, the Chief Medical Officer of Allurion Technologies, Inc., was granted stock options to purchase 204,082 shares of common stock.
• The exercise price of these options is $2.20 per share.
• 25% of the options will vest on May 2, 2025, with the remaining options vesting in 36 equal monthly installments thereafter, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The vesting schedule suggests a long-term commitment from the Chief Medical Officer to Allurion Technologies.

Industry Context

Stock options are a common form of executive compensation in the technology and healthcare industries, used to attract and retain talent and align their interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the medical device industry.
• Companies like Medtronic, Boston Scientific, and Stryker also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance and commitment.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with long-term value creation.
• Employees may see this as a positive indicator of the company's commitment to its leadership team.

Key Dates